New daTABASE IN THE THEW: 1,172 HOlter recordings from patients with chest pain
The THEW signed an agreement with University of California San Francisco for transferring the data from the IMMEDIATE AIM (Ischemia Monitoring and Mapping in the Emergency Department In Appropriate Triage and Evaluation of Acute Ischemic Myocardium) in to the THEW. This dataset includes digital ECG data recorded from 2001-2005 with Mason-Likar 12-lead Holter monitor devices (average length of recordings, 15.9 hours ± 9.0). The database includes 1154 subjects (230 GB), 547 patients had a final diagnosis of acute coronary syndrome - ACS (105 with acute myocardial infarction; 178 with unstable angina), 607 with non-ACS cardiac diagnosis (e.g., heart failure, arrhythmia), and 271 had a non-cardiac diagnosis (e.g., gastrointestinal reflux disease). Demographic information, coronary risk factors, medical history and clinical data (serum troponin, cardiac catheterization, hospital length of stay and complications, transient ischemic events, and 1-year mortality) are available. To learn more about this new dataset click here.
| Accessing the data from the THEW |
To access the data from the warehouse, you can request for a demo. version of the THEW Client Application which let you connect to a database containing Holter ECGs from the repository. To access to all data from the THEW , register and become member of our initiative here. The THEW is a not-for-profit organization. |
| About Us |
The Steering Committee (SC) of the Telemetric and Holter ECG Warehouse (THEW) has been formed during the second quarter 2008, the nine individuals in the SC are from the National Health Institute, the Center for Drug Evaluation and Research, the Commissioner Office of the Food and Drug Administration (FDA) and the University of Rochester Medical Center. Read more about our team. |
Keep informed about our activities by joining our LinkedIn group. More than 292 professionals have already registered.
[12/16/2009]: The Director of the THEW interviewed by Technology Review published by the MIT: here.
[11/11/2009]: New Research Center to Focus on Cardiac Safety and Innovation in Pharmaceutical Industry Today: here.
[6/11/2009]: University of of Rochester and FDA Partner for ECG Database, Drug Discovery & Development Magazine. More info here
[5/6/2009] FDA website Existing Partnerships FDA’s Public-Private Partnership Program: THEW
[03/28/2009] Public and Private part- nership to help determine Clinical Biomarker Utility in Applied Clinical Trials online.com.>here
[7/26/2010] Members: Angel Medical System Inc. has joined the THEW initiative. Angel Medical Systems develops and markets cardiac devices that provide heart monitoring, alerting, and data collection. Their AngelMed Guardian system is an iimplantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions.
[7/12/2010] The THEW quoted in a recent issue of the Journal of the American College of Cardiology. In a reply to a correspondence from Dr. Verrier and Nieminen on the role of T-wave alternans in hospital monitoring for torsades de pointes, Dr. Drew quoted the THEW as " a less expensive (than prospective clinical trials) and immediate available research strategy ... to validate ECG monitoring algorithms." JACC Vol. 56, No 3., 23010, 238-42.
[1/13/2010] Members: The Oxford University Computing Laboratory is the first new member for year 2010. At the heart of computing and related interdisciplinary activity at Oxford, this centre focuses on research in computer science, numerical analysis, computational biology, quantum computation, computational linguistics, and information systems. The Computational Biology Group also plays a key role in interdisciplinary initiatives across the University, including the EU FP7 projects euHeart and PreDiCT.
[05/27/2008]: "THEW Beyond QT working Group" releases an ECG marker submission form designed in collaboration with the FDA.
NHLBI Support[12/13/2009]:The University of Rochester and the NHLBI enabled the creation of a "Center for Quantitative Electrocardiography and Cardiac Safety" (CES). Read more...
Agreement[05/27/2008] FDA: Dr. J. Woodcock (Director, CDER-FDA) and Dr. Norman Stockbridge (Director for the Division of Cardiovascular and Renal Products, CDER-FDA) signed a Letter of Agreement officially starting the partnership between the FDA and University of Rochester for the THEW initiative. More...